

AD

(Leave blank)

Award Number:
W81XWH-08-1-0183

TITLE:
Molecular Basis of Autophagic Cell Death in Prostate Cancer

PRINCIPAL INVESTIGATOR:
Ramesh Kaini

CONTRACTING ORGANIZATION:
University of New Mexico
Albuquerque, NM, 87131-0001

REPORT DATE:
March 2009

TYPE OF REPORT:
Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

- ☒ Approved for public release; distribution unlimited
- ☐ Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 31-03-2009		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 1 Mar 2008 - 28 Feb 2009	
4. TITLE AND SUBTITLE Molecular Basis of Autophagic Cell Death in Prostate Cancer				5a. CONTRACT NUMBER W81XWH-08-1-0183	
				5b. GRANT NUMBER GRANT00264242	
				5c. PROGRAM ELEMENT NUMBER	
				5d. PROJECT NUMBER	
6. AUTHOR(S) Ramesh Kaini				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of New Mexico Albuquerque, NM, 876131-0001				8. PERFORMING ORGANIZATION REPORT	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S.Army Medical Research and Material Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT To understand the molecular basis of autophagy in prostate cancer, I am trying to isolate pure autophagosomes from autophagic cell survival and autophagic cell death Prostate cancer cell model and profile proteins and lipids to identify autophagy abundant/specific proteins and lipid molecule that are essential for functional autophagy in prostate cancer. I established EGFP.LC3 stably expressing LNCaP cell line and characterized the autophagic activity by western blot, translocation assay and Atg5 siRNA transfection. I also confirmed the autophagic activity in PC3.EGFP.LC3 cells. I was able to enrich autophagosomes using gradient ultracentrifugation and currently trying to optimize the condition for further purification by Immunopurification using beads.					
15. SUBJECT TERMS Autophagy, Prostate cancer, Subcellular Organelle Purification					
16. SECURITY CLASSIFICATION OF:				17. LIMITATION OF ABSTRACT UU	1 8. N U
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	2 8		19a. NAME OF RESPONSIBLE PERSON USAMRMC
					19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusion.....	8
References.....	8
Appendices.....	9

Introduction:

I, Ramesh Kaini, PI of the project (Title: Molecular Basis of Autophagic Cell Death, contract no.: W81XWH-08-1-0183); was awarded FY07 Prostate Cancer Training Award (Pre-doctoral -PhD) to pursue my career in prostate cancer research. The purpose of the award is to support me to understand the molecular basis of autophagy and its role in cell survival and cell death of prostate cancer cells in response to different stimuli. My focus is to isolate autophagosomes from both autophagic cell death and autophagic cell survival prostate cancer cell models and profile proteomes and lipidomes to identify novel autophagy abundant and/or specific protein and lipid molecules that are essential for functional autophagy in prostate cancer cells. The project consists of three aims : (i) to create autophagic cell death and autophagic cell survival models in LNCaP (P53^{+/+}) and PC-3 (P53^{-/-}) cells; (ii) to purify autophagy abundant and specific vacuoles, autophagosomes and autolysosome; and (iii) to profile and characterize membrane protein and lipid species of autophagosomes and autolysosome using quantitative proteomic and lipidomic approaches.

Body:

A. Training Accomplishments:

This year, I mainly focused to update my knowledge and expertise in cancer biology, autophagy and required techniques. Notable was my “The Edward A. Smuckler Memorial Workshop” award to attend the “AACR Workshop in Cancer Research: Pathobiology of Cancer” at Snowmass village, CO from July 6-13, 2008. The intense one week long workshop was very helpful for me to widen my knowledge in cancer pathogenesis at molecular and morphologic level from some of the best scientists working in the field. I also continued to actively participate in CMBD seminar, departmental journal club, pathology grand round and cancer center visiting professor lectureship. These seminars/ journal club / grand rounds continue to help me to widen my knowledge in multiple disciplines of biomedical science. Besides, participation in regular prostate cancer interest group meeting was also productive for me to update with recent advances in prostate cancer research.

Throughout year, my mentor Dr. Andy Hu was very supportive in providing guidance and research support. He was always there when I need help. He was also very keen on helping me to develop professionalism. This year, he also provided me an opportunity to assist in peer-reviewing an article. It was a great experience for me to critically analyze a review paper and provide comments in a professional way. My co-mentor, Dr. Laurel Sillerud was also very supportive to guide me through the problems encountered during research. I have also regular interaction with other advisors, Dr. Bisoffi & Dr. Deretic.

This year, I learned and applied the techniques, gradient ultracentrifugation and confocal microscopy. I also learned the principle and sample preparation for electron microscopy and flow cytometry.

As of Fall 2008; I have earned 88 credit hours with cumulative GPA of 3.87.

B. Research Accomplishments:

There are three specific aims of my project as outlined previously in the introduction. The target was to achieve Specific Aim 1 and 2 in the first two years and Specific Aim 3 in the third year.

Accomplishments for Aim 1:

I successfully transfected the LNCaP cells with pEGFP.LC3 plasmid construct (gift from Dr. Noburu Mizushima) and generated stably transfected clone of LNCaP cells. Stably transfected cells were selected by continuously growing the transfected cells under G418 selective pressure (400 ug/ml). During autophagy, cytosolic EGFP.LC3 are processed and targeted to newly forming autophagosomes which are observed as distinct puncta under the fluorescence microscopy (1-2). I induced autophagy by incubating LNCaP.EGFP.LC3 cells in starvation medium and assessed autophagy by observing the translocation of diffused cytosolic recombinant EGFP.LC3 protein to distinct puncta (Fig. 1A,B). Autophagic activity was quantified by calculating the percentage of cells showing distinct puncta over different time points of starvation (Fig. 1C). Similar results were observed in pEGFP.LC3 stably transfected PC3 prostate cancer cell line (obtained from Dr. wei-Pang Hwang).




Figure 1. Starvation induces autophagy formation in LNCaP-EGFP.LC3 cells. (A) Cytosolic localization of EGFP.LC3 in stably transfected LNCaP cells. (B) Translocation of EGFP.LC3 in puncta after incubation in HBSS in LNCaP-EGFP.LC3 cells. (C) Quantitation of EGFP.LC3 puncta formation in stably transfected LNCaP cells at different time points after incubation in HBSS. Cells were grown in cover slip and then incubated in HBSS as noted. Six visual fields were selected in random for each group. All cells in each field were counted (minimum number of 350 cells) and the percentage of cells with puncta formation was calculated.

Exogenously expressed EGFP.LC3 can sometime aggregate and show distinct puncta formation independent of autophagic activity (2,3). Atg5 is a key molecule required for the formation of autophagosomes(1-3). I did Atg5 siRNA transfection in EGFP.LC3 stably expressing LNCaP cells and observed that knocking down of Atg5 abrogated the translocation of cytosolic EGFP.LC3 to distinct puncta (fig 2). This confirmed that my EGFP.LC3 transfected cells are bonafide autophagic model.




Figure 2. ATG5 knockdown abrogates autophagy formation in LNCaP-EGFP.LC3 cells. Transfection of ATG5 siRNA was performed using the Lipofectamine 2000 and the supplied protocol. Translocation assay was performed 48 hours post-transfection. ATG5 siRNA at 25 nM concentration reduces the autophagy formation by starvation in HBSS.

Currently, I am working forward to characterize proposed autophagic cell survival model by using sulforaphane. ApoL1 induced autophagic cell death is defined in the attached two co-authored papers (Appendices 1, 2).

Accomplishments for Aim 2:

To establish the method for isolation and purification of autophagosomes from LNCaP-EGFP.LC3 cells and PC3-EGFP.LC3 cells induced by starvation in HBSS medium (pro-survival); I initially enriched the autophagic fraction by differential centrifugation. I biotinylated the antibodies against LC3 and conjugated with streptavidin coated magnetic beads. Then, the enriched autophagic fraction was incubated with Anti-LC3-Mag-Nap and the bound organelle fraction was washed three times. However, thus purified autophagosomes was not pure enough for downstream proteomic and lipidomic study on multiple repeated attempts.

As discussed earlier, the recombinant protein EGFP.LC3 translocates to autophagic membrane during autophagosomes formation. So, I used antibody against EGFP to selectively immunopurify autophagosomes, but the result was similar to that obtained by using antibody against LC3. Intracellular lysosomes have been purified using flow cytometry assisted organelle sorting (FAOS) (4). To take advantage of selective localization of EGFP.LC3 in the autophagosomes; I tried to sort out autophagosomes using flow cytometry assisted organelle sorting as an alternative method to

isolate autophagosomes. However, the signal was not enough to detect by the flow cytometry and that approach was aborted.

Another promising method to purify intracellular organelles is gradient ultracentrifugation. I tried to enrich autophagosomes by using sucrose gradient followed by immunopurification using antibodies tagged with magnetic particles. Previously, rat liver autophagosomes were also purified by using nycodenz/ percoll gradient (6). I attempted to imply the same methods to purify autophagosomes. Both methods work to highly enrich the autophagosomes.



RK2Ab41ow.tif
D09-1
RK-2A-b
Cal: 289.546pix/micron
14:48 01/20/09

500 nm
HV=80kV
Direct Mag: 5000x

Figure 3: Electron-micrograph of isolated autophagosomes using Anti-EGFP-Mag-Nap after separation of intracellular organelles using sucrose gradient ultracentrifugation. Beads, autophagosomes and contaminating organelles are seen in the picture.

I'm further trying to optimize the condition for Immunopurification of these purified autophagosomes from density gradient centrifugation, by using antibody against LC3 or EGFP that are conjugated with beads. I hope, immunopurification after the successful density gradient ultracentrifugation will yield enough pure autophagic samples for my downstream proteomic and lipidomic study. Based on contamination level, I plan to imply negative selection of contaminants before positive selection of autophagosomes using beads tagged with antibody against the molecular marker of contaminating organelles.

Key Research Accomplishments:

- # Successfully established stably transfected LNCaP.EGFP.LC3 cells.
- # Characterized and confirmed the autophagic activity in LNCaP.EGFP.LC3 cells by western blot, translocation assay and Atg5 siRNA transfection experiment.
- # Confirmed autophagic activity in PC3.EGFP.LC3 cells.
- # Co-authored and documented ApoL1 induced autophagic cell death model.
- # Obtained purified autophagosomes from gradient ultracentrifugation.

Reportable Outcomes:

1. LNCaP.EGFP.LC3 cells.
2. Wan G, Zhaorigetu S, Liu Z, **Kaini R**, Jiang Z, Hu CA: Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem 2008; 283(31):21540-9.
3. Zhaorigetu S, Wan G, **Kaini R**, Jiang Z, Hu CA: ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008; 4(8):1079-82.

Conclusion:

I completed the most part of Aim 1 and am currently trying to optimize the purification of autophagosomes using density gradient and immunopurification. I'm hopeful that I'll complete the remaining part on Aim 1 and Aim 2 before the completion of year 2 of funding as targeted.

I also widened my breadth of knowledge a lot on prostate cancer, cancer pathogenesis and other discipline of biomedical science through various workshops, didactic journal club/ seminars/ grand rounds and group meeting.

References:

1. Mizushima N, Ohsumi Y, Yoshimori T: Autophagosome formation in mammalian cells. Cell Structure & Function 2002; 27:421-429
2. Klionsky DJ et al : Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4(2): 151-175

3. Ciechomska IA & Tolkovsky AM: Non-autophagic GFP-LC3 puncta induced by saponin and other detergents. *Autophagy* 2007; 3(6) : 586-590
4. Rajotte D, Stearns CD, Kabcenell AK : Isolation of mast cell secretory lysosomes using flow cytometry. *Cytometry* 2003; 55A(2): 94-101
5. Strømhaug PE, Berg TO, Fengsrud M, Seglen PO : Purification and characterization of autophagosomes from rat hepatocytes. *Biochem J* 1998; 335(2): 217-224

Appendices

Apolipoprotein L1, a Novel Bcl-2 Homology Domain 3-only Lipid-binding Protein, Induces Autophagic Cell Death*

Received for publication, January 9, 2008, and in revised form, May 26, 2008. Published, JBC Papers in Press, May 26, 2008, DOI 10.1074/jbc.M800214200

Guanghua Wan, Siqin Zhaorigetu, Zhihe Liu, Ramesh Kaini, Zeyu Jiang, and Chien-an A. Hu¹

From the Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131

The Bcl-2 family proteins are important regulators of type I programmed cell death apoptosis; however, their role in autophagic cell death (AuCD) or type II programmed cell death is still largely unknown. Here we report the cloning and characterization of a novel Bcl-2 homology domain 3 (BH3)-only protein, apolipoprotein L1 (apoL1), that, when overexpressed and accumulated intracellularly, induces AuCD in cells as characterized by the increasing formation of autophagic vacuoles and activating the translocation of LC3-II from the cytosol to the autophagic vacuoles. Wortmannin and 3-methyladenine, inhibitors of class III phosphatidylinositol 3-kinase and, subsequently, autophagy, blocked apoL1-induced AuCD. In addition, apoL1 failed to induce AuCD in autophagy-deficient *ATG5*^{−/−} and *ATG7*^{−/−} mouse embryonic fibroblast cells, suggesting that apoL1-induced cell death is indeed autophagy-dependent. Furthermore, a BH3 domain deletion construct of apoL1 failed to induce AuCD, demonstrating that apoL1 is a *bona fide* BH3-only pro-death protein. Moreover, we showed that apoL1 is inducible by p53 in p53-induced cell death and is a lipid-binding protein with high affinity for phosphatidic acid (PA) and cardiolipin (CL). Previously, it has been shown that PA directly interacted with mammalian target of rapamycin and positively regulated the ability of mammalian target of rapamycin to activate downstream effectors. In addition, CL has been shown to activate mitochondria-mediated apoptosis. Sequestering of PA and CL with apoL1 may alter the homeostasis between survival and death leading to AuCD. To our knowledge, this is the first BH3-only protein with lipid binding activity that, when overproduced intracellularly, induces AuCD.

Bcl-2 family members play crucial roles in regulating programmed cell death (PCD).² In stressed cells the live-or-die

decision is largely determined by interplay between opposing members of the Bcl-2 protein family (1–4). Each member of the Bcl-2 family contains at least one of four conserved amino acid (aa) sequences, Bcl-2 homology (BH) domains 1–4. Based on their function in PCD, the Bcl-2 family members can be divided into three subgroups as follows: multi-BH domain anti-death, multi-BH domain pro-death, and BH3-only pro-death (1–3). The BH3 domain is conserved across all Bcl-2 family members and is the only domain retained by BH3-only proteins, further emphasizing the functional significance of this domain (4). In mammals, there are two major types of PCD, apoptosis and autophagic cell death (AuCD). Apoptosis (type 1) is characterized by nuclear condensation/DNA fragmentation and cell membrane alteration, without major ultrastructural changes of subcellular organelles. It usually involves the activation of caspases as well as the release of apoptogenic effectors, such as cytochrome *c* and apoptosis-inducing factor, from mitochondria that contribute to the acquisition of the apoptotic morphology (5–8). The molecular basis of AuCD (type 2), however, is not as well characterized in mammalian cells, even though many lines of evidence connect autophagy to human disease. Autophagy is generally defined as a lysosome-dependent mechanism of intracellular degradation that is used for the turnover of cytoplasmic constituents. There are three major classifications of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (9–12). Macroautophagy (hereafter referred to as autophagy) is a highly conserved eukaryotic catabolic process involving the sequestration of the cargo (*i.e.* fraction of cytosol or organelles) within double membranes, creating autophagosomes, which then fuse with the endosome and lysosome to create autolysosomes. In the lumen of autolysosomes, lysosomal enzymes operate at low pH to catabolize the autophagic material (12–14). Autophagosomes and autolysosomes, also called autophagic vacuoles (AV), are considered to be *de novo* subcellular organelles specific to the autophagic process. Autophagy allows cells to eliminate large portions of the cytoplasm and is directly involved to eliminate aberrant protein aggregates, remove damaged/

* This work was supported, in whole or in part, by National Institutes of Health Grant 5R01CA106644-01A1 from NCI and New Mexico-IdeA Network of Biomedical Research Excellence (NM-INBRE) Program P20RR016480-04 (to C.-A. A. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, MSC08 4670, 1 University of New Mexico, Albuquerque, NM 87131-0001. Tel.: 505-272-8816; Fax: 505-272-6587; E-mail: Ahu@salud.unm.edu.

² The abbreviations used are: PCD, programmed cell death; AuCD, autophagic cell death; AV, autophagic vacuoles; BH, Bcl-2 homology domain; CL, cardiolipin; LC3, microtubule associated proteins light chain 3; PA, phosphatidic acid; PI, phosphatidylinositol; PI3K, phosphatidylinositol 3-phosphate kinase; PIP, phosphoinositide; 3-MA, 3-methyladenine; PARP, poly-

(ADP-ribosyl) polymerase; TEM, transmission electron microscopy; aa, amino acid; mTOR, mammalian target of rapamycin; MEF, mouse embryonic fibroblast; RT, reverse transcription; BSA, bovine serum albumin; HBSS, Hanks’ balanced salt solution; PE, phosphoethanolamine; PG, phosphoglycerol; PI, phosphatidylinositol; SM, sphingomyelin; TG, triglyceride; AD, adenovirus; Dox, doxycycline; HDL, high density lipoprotein; PI-3,4,5-P₃, phosphatidylinositol 3,4-trisphosphate; PI-3,4-P₂, phosphatidylinositol 3,4-bisphosphate; PI3P, phosphatidylinositol 3-phosphate; PI4P, phosphatidylinositol 4-phosphate; Ptd, phosphatidylinositol.

aged organelles, defend against pathogen invasions, and cover an essential role in early neonatal development and differentiation (15–16). Upwards of 20 autophagy-related genes (*ATG*) have been identified, which regulate and/or directly participate in the autophagic pathway, particularly in AV formation (10, 13, 14). Deficiency of *ATGs* for example, *ATG5* and *ATG7*, causes loss of AV formation and subsequently lack of autophagic response. These deficiencies correlate with various diseases such as cancer, cardiomyopathy, and neurodegenerative diseases (17–22). Paradoxically, recent evidence suggests that autophagy is, on the one hand, a survival pathway necessary to sustain mammalian viability during periods of starvation, and on the other hand, progressive autophagy can be a means to cell death (7, 11, 12). Significantly, Berry and Baehrecke (23) reported that autophagy is involved in physiological cell death during *Drosophila* development but is controlled by similar mechanisms as those that control autophagy function in cell survival. Furthermore, they provide *in vivo* evidence that both growth arrest and autophagy are required for physiological AuCD. However, the molecular determinants that dictate the control of autophagy for cell survival or death have not yet been revealed.

Aside from their role in apoptosis, the members of the Bcl-2 family also play an important role in autophagy. For example, when treating apoptosis-deficient cells, such as BAX and BAK double knock-out cells, with cytotoxic compounds (for example, etoposide), the primary response of those cells was AuCD, suggesting that homeostatic states of these knock-out Bcl-2 members play pivotal roles in regulating AuCD (24–27). In addition, it has been shown that the anti-death Bcl-2 and Bcl-xL can bind and inhibit Beclin1, a mammalian ortholog of yeast *ATG6*, and subsequently inhibit autophagy (28, 29). Overexpression of Beclin1 has been shown to induce formation of AV and autophagy in mammalian cells (28). Interestingly, Beclin1 has been found to be a haploinsufficient tumor suppressor frequently mutated/deleted in breast, prostate, and ovarian cancers (12, 30, 31). Heterozygous knock-out mice of Beclin1 (*Beclin1*^{+/-}) are tumor-prone, suggesting that autophagy has a tumor suppression function (30). Importantly, structural and functional analyses showed that Beclin1 is a novel BH3-only protein, and this BH3 domain within Beclin1 mediates associations with Bcl-2 and Bcl-xL (32–34). In addition to Beclin1, recent studies showed other BH3-only members that also play regulatory roles in autophagy in physiological context. For example, Bid, a BH3-only protein, showed involvement in regulating both apoptosis and autophagy in breast cancer MCF-7 cells (35). Bad and BNIP3, two other BH3-only proteins, when overexpressed, can induce formation of AV in cancer cells (34, 36, 37). Interestingly, Bid, Bad, and BNIP3 are downstream targets of p53, a well characterized tumor suppressor and transactivating factor. It has been shown that p53 plays a critical role in the suppression of tumorigenesis, in part, by the induction of both type I and type II PCD (38–41).

To identify and characterize novel BH3-only proteins in AuCD and discover molecular regulators that dictate autophagy for death or survival, in this study, we utilized *in silico* data base-mining, functional expression, microscopy strategies, and

lipid binding assay to examine a novel BH3-only protein, apolipoprotein L1 (apoL1).

EXPERIMENTAL PROCEDURES

Cell Lines, Chemicals, and Culture Media—DLD-1.TA14 (a p53-null, “Tet-Off” inducible colorectal cancer cell line) and Hec50co (a p53-null endometrial cancer cell line) and their corresponding growth medium and condition have been described previously (42–44). *ATG5*^{-/-} and *ATG7*^{-/-} mouse embryonic fibroblast (MEF) cells were gifts from Dr. Mizushima (15) and Dr. Komatsu (16), respectively. HEK293 and AD293 cell lines were purchased from ATCC and Clontech, respectively. All cell lines except DLD-1 were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and 1% antimicrobial agents as described previously (44).

Identification and Sequence Analysis of Novel BH3-only Proteins by Functional Genomics and Biocomputing Approaches—The known BH3 domain consensus sequence and a data base-mining strategy were utilized to probe human genome and proteome data bases for the identification of novel BH3-only proteins as described previously (45). The annotated human open reading frames of candidate genes were downloaded from the most recent NCBI data base (build 36.2). In addition, candidate proteins were assessed for other putative domains/motifs, utilizing public sequence analysis programs and tools, such as the ExPASy proteomics server and ClustalW, as described previously (45). In addition, protein tertiary structure prediction was obtained from HMMSTR/ROSETTA (46, 47), and presentations of tertiary structure were made using Protein Data Bank files created with HMMSTR/ROSETTA and PyMOL.

Cloning of Human ApoL1 cDNA and Generation of Inducible ApoL1 Gene—Human apoL1 was identified as a putative BH3-only protein by *in silico* data base mining. PCR was used to amplify the 1,194-bp full-length apoL1 cDNA. Subsequently, the sequence-confirmed apoL1 and apoL1 with a C-terminal FLAG tag (apoL1.FLAG) were cloned into pBI-EGFP vector (Clontech). The primers used for amplifying apoL1 were as follows: reverse, 5′-CCGCTCCAGTCACAGTTCTTGGTC-3′ (bp +1,197 to +1,183), and forward, 5′-CGACGCGTATGGAGGGAGCTGCTTTGC-3′ (bp +1 to +19). The reverse primer used for amplifying apoL1.FLAG was 5′-CTAGCTAGCTCACTTATCGTCGTCATCCTTGTAATCCAGTTCTTGGTC-3′ (bp +1,197 to +1,183). The resulting plasmids were used to transfect a previously described “Tet-Off” inducible system in DLD-1.TA14 (44, 45). Stably transfected DLD-1 cells harboring pBI-apoL1 or pBI-apoL1.FLAG, namely DLD-1.apoL1 and DLD-1.apoL1.FLAG, respectively, were selected in noninduction medium (D.20) with 20 ng/ml doxycycline (Dox) as described previously (44, 45). We assayed inducible expression of apoL1 transcripts by semi-quantitative RT-PCR and immunoblot analyses.

Site-specific Deletion Mutagenesis—To generate the BH3 domain deletion allele of apoL1, that is to delete the 27 bp that encode the 9-amino acid BH3 domain (codons 158–166; base pairs +474 to +498), a PCR-based site-directed mutagenesis kit (ExSite, Stratagene) and the deletion-specific primers were used. Primer sequences were as follows: forward, 5′-AAGGTCC-

ACAAAGGCACCACC, and reverse, 5'-(p)CCTTCTTATGTT-ATCCTACAGC. The deletion construct pBI-apoL1.dBH3 was confirmed by sequencing and was used to construct pAD-apoL1.dBH3 plasmid as described above (44).

ApoL1 Adenovirus (AD-ApoL1)—Construction, amplification, and assaying for titers of adenoviruses (AD) harboring apoL1 and apoL1.dBH3 alleles, and viral infection of mammalian cells were performed as described previously (44). A variety of cells were infected with control AD, AD-apoL1, and AD-apoL1.dBH3 with a range of concentrations from 0.01 to 5 multiplicity of infection (or plaque-forming units/cell, which was estimated to be 0.2–100 virus particles/cell) for 3 days. Cell numbers, cell death, and survival were measured over time by counting the attached cells, and by microscopy analysis in cell morphology (roundup) and increase of intracellular vacuole formation.

Semi-quantitative RT-PCR—Total RNA was isolated from cells using a Purescript kit (Gentra Systems). RT was conducted using random hexamers, and PCR was conducted using gene-specific primers and a standard protocol as described (36, 37). The primers used for PCR were as follows: reverse, 5'-CCGC-TCCAGTCACAGTTCTTGGTC-3' (bp +1,197 to +1,183), and forward, 5'-CAGCAGTACCATGGACTACGG3' (bp +672 to +692).

Generation of Anti-peptide Antibodies against Human ApoL1—To raise anti-peptide antisera specifically against human apoL1, a peptide corresponding to the codons 384–398 of apoL1 (ILNNYKILQADQEL) was used to immunize rabbits (Anaspec). Antibody was affinity-purified by chromatography on peptide (antigen)-linked Sepharose and designated as anti-apoL1.

Immunoblot Analysis—Total cellular extracts were isolated and used for immunoblot analysis from indicated cells as described previously (42, 43). Proteins were separated using 10% SDS-PAGE (20 μ g of protein/lane) and transferred to nitrocellulose membranes, which were then incubated with anti-apoL1, anti-activated caspase-9 (Cell Signaling Technology), anti-caspase 8 (Cell Signaling), anti-caspase 3, anti-poly-(ADP-ribosyl) polymerase (PARP) (Santa Cruz Biotechnology), anti-LC3 (MBL), and anti- β -actin (Oncogene Research Products). Subsequently, blots were incubated with goat anti-rabbit or anti-mouse horseradish peroxidase-labeled secondary antibodies (Bio-Rad).

Analysis of Dose-dependent, Time Course-dependent Cell Death—Taking advantage of the inducibility of the Tet-Off system, dose-dependent and time course-dependent cell death studies were conducted. Briefly, stably transfected DLD-1.apoL1 or DLD-1.apoL1.FLAG cells were grown in D.20. For induction studies, adherent cells were rinsed in phosphate-buffered saline, refed with the induction medium containing gradually decreasing concentrations of Dox (5 ng/ml, D.5; 1 ng/ml, D.1; 0 ng/ml, D.0), and harvested at the indicated time points as described previously (31, 38).

Assay of Protein Localization by Immunofluorescence Microscopy—Cells were grown on glass coverslips coated with collagen (Roche Applied Science). After induction of apoL1 for various times, cells were rinsed and then fixed with 4% (v/v) paraformaldehyde solution at room temperature. Coverslips were rinsed twice with HBSS and blocked with 3% (w/v) BSA in

TBST for 30 min at room temperature. After incubation overnight at 4 °C in 3% (w/v) BSA containing the anti-LC3 antibody (P0036, MBL), coverslips were rinsed with HBSS four times and incubated in 3% (w/v) BSA in TBST containing Texas Red-labeled secondary antibody (T2767, Invitrogen) for 1 h at room temperature. Finally, coverslips were rinsed with HBSS, mounted onto slides, and subjected to fluorescent microscope analysis.

Transmission Electron Microscopy—Cells on coverslips were fixed in 3% formaldehyde, 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 45 min, washed, and finally fixed for 1 h in 1% osmium tetroxide, 0.5% potassium ferrocyanide in cacodylate buffer. The samples were then washed again, dehydrated with graded alcohol, and embedded in Epon-Araldite resin (Canemco). The resin was cured at 65 °C for 2 days, after which the glass coverslips were removed from the resin blocks and the samples were sectioned. Ultrathin sections were collected on copper grids and examined in an Hitachi H-7500 electron microscope. Images were captured and processed with an AMT XR60 B camera and Image Capture software version 5.42.

Effect of 3-Methyladenine (3-MA), Wortmannin, and ATGs on ApoL1-induced Cell Death—To investigate whether apoL1-induced cell death was through autophagy, two different experiments were conducted. First, 3-MA (5 mM) and wortmannin (1 μ g/ml), two inhibitors of PI3Ks and autophagy, were added to DLD-1.apoL1 cells 8 h prior to the induction of apoL1. Cell death was monitored by light microscopy analysis 24 h after apoL1 induction. Second, wild type (WT), *ATG5*^{-/-}, and *ATG7*^{-/-} MEF cells were infected with AD-apoL1. Induction of cell death, overexpression of apoL1, and activation of LC3-II were assays 36 h after viral infection.

Induction, Immunoprecipitation, and Elution of the ApoL1.FLAG Fusion Protein—DLD-1.apoL1.FLAG cells were grown in the induction medium for 24 h, rinsed twice with cold phosphate-buffered saline, pelleted, and lysed in lysis buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100). Total soluble protein extract was incubated with Anti-FLAG-agarose affinity gel (Sigma, F2426) at 4 °C overnight with gentle agitation. The agarose beads were then washed two times with ice-cold TBS (50 mM Tris-HCl and 150 mM NaCl, pH 7.4) and incubated with 400 μ l (150 ng/ μ l) of 3 $\times$ FLAG peptide (Sigma, F4799) in TBS at 4 °C overnight for eluting apoL1-FLAG fusion protein.

In Vitro Lipid Binding Assay—Similar to an immunoblot analysis, phosphoinositide (PIP), and membrane lipid strips, nitrocellulose membranes pre-spotted with various indicated lipid species (P-6001, P-6002, Echelon, Salt Lake City, UT) were blocked in 3% fat-free BSA for 60 min at room temperature, probed with the purified apoL1.FLAG protein (~100 ng/ml) in 3% fat-free BSA in TBST for 1 h at room temperature, followed by primary anti-apoL1 antibody, secondary goat anti-rabbit antibody conjugated with horseradish peroxidase, and ECL detection and imaging.

RESULTS

ApoL1 Is a BH3 Domain Containing Protein—We utilized a 9-residue consensus sequence of the BH3 domain constructed from known human Bcl-2 proteins to probe the human proteome data base that identified a BH3 domain embedded in the




FIGURE 1. Sequence and domain analysis of human apoL1. A, polypeptide sequence alignment of human apoL1 and apoL6. Over all, apoL1 and apoL6 shows 27% identity and 42% similarity at the aa level. Putative domains in apoL1 include a BH3 domain (aa 158–166) and a leucine zipper domain (aa 365–392). B, sequence alignment of the 20-aa region containing putative BH3 domain in known BH3-only proteins (PUMA, BAD, NOXA, and apoL6) and apoL1 and apoL4. The 9-aa BH3 domain are in **boldface** and the two amino acids, L and D, which are conserved in all known BH3 domains, are labeled in **red** with asterisks. ApoL4 does not possess the conserved Asp residue, instead, it is substituted by an Asn (in **blue**). C, predicted tertiary structure of the 20-aa region containing putative BH3 domain in the indicated proteins. As expected, the 9-aa BH3 domains of known BH3-only proteins, PUMA, BAD, NOXA, and apoL6, show amphipathic α -helical structures. Importantly, the putative BH3 domain of apoL1 also possesses an α -helical domain. In contrast, apoL4 does not possess a complete, canonical α -helical structure in that region.

apoL1 (GenBankTM accession number NM_003661). We then retrieved full-length cDNA and protein sequences of apoL1 from the National Center for Biotechnology Information

(NCBI) (ncbi.nih.gov) nucleotide and protein sequence data bases. Previously, using the same methodology, we reported the cloning and characterization of a *bona fide* BH3-only pro-death gene apolipoprotein L6 (apoL6) and showed that overexpression of apoL6 induces mitochondria- and caspase 8-mediated apoptosis (45). Both apoL1 and apoL6 belong to a newly identified apolipoprotein L family that share significant sequence identity within the predicted amphipathic α -helix. Besides apoL1 and L6, apoL family has four other members, L2–5. It has been suggested that these proteins play important roles in lipid binding and transport (48–50). Sequence analysis showed that apoL1 possesses a putative BH3 domain (aa 158–166) with 67% sequence identity with that of apoL6 (Fig. 1A). Over all, apoL1 and apoL6 possess 27% sequence identity and 42% similarity at the polypeptide level. In addition to the putative BH3 domain, apoL1 also possesses a leucine zipper domain (aa 365–392) (Fig. 1A). Sequence alignment of the 20-aa putative BH3 domain with a number of known BH3-only proteins (PUMA, BAD, NOXA, and apoL6) and apoL4, further showed that the 9-aa BH3 domain of apoL1 harbors the two important amino acids, Leu and Asp, conserved in all known BH3 domains (2, 4). By contrast, apoL4 does not possess the conserved Asp residue, which is substituted by an Asn instead (Fig. 1B). Tertiary structure prediction, of the 20-aa putative BH3 domain in the indicated proteins, showed that the 9-aa BH3 domain of apoL1 possessed amphipathic α -helical structure, similar to other BH3-only proteins of PUMA, BAD, NOXA, and apoL6 (Fig. 1C). In contrast, apoL4 does not possess a canonical α -helical structure in that region (Fig. 1C). Finally, sequence analysis suggests that apoL1 does not possess BH1, BH2, or BH4 domains. Taken together, these results suggest that apoL1 is a putative BH3-only protein.

ApoL1 Induces Cell Death in a Variety of Cell Types—To investigate whether apoL1 induced cell death, we constructed a




FIGURE 2. Time- and dose-dependent induction of apoL1 and cell death in DLD-1.ApoL1 cells. Induction of apoL1 expression is time-dependent as indicated by semi-quantitative RT-PCR using total RNA (A) or immunoblot analysis using total soluble proteins isolated from cells grown in induction medium (D.0) for the indicated time (B). C, apoL1 induces dose-dependent cell death. DLD-1.apoL1 cells were cultured in media containing Dox (D; ng/ml) as indicated. Attached cells were harvested and counted after 48 h. D, apoL1 induces time-dependent cell death. DLD-1.apoL1 cells were cultured in D.20 (Dox, 20 ng/ml) medium (squares) or D.0 (Dox, 0 ng/ml) medium (triangles), harvested, and counted at the times indicated. Each experiment was repeated at least three times. *, $p < 0.05$, indicates significant difference compared with control by Student's *t* test.

Tet-Off apoL1-inducible system in DLD-1 cells (DLD-1.apoL1) and adenovirus harboring wild type apoL1 (AD-apoL1) or a BH3 domain deletion construct of apoL1 (AD-apoL1.dBH3). We first examined whether apoL1 expression was inducible in a time-dependent manner in stably transfected DLD-1.apoL1 cells. Using semi-quantitative RT-PCR and total RNA isolated from DLD-1.apoL1 cells induced for 0, 6, 12, 24, and 48 h, we showed that there was time-dependent induction of apoL1 in induced DLD-1.apoL1 cells at the RNA level (Fig. 2A). We observed that expression of apoL1 was increased ~4-fold 12 h after the removal of Dox (Fig. 2A). ApoL1 transcripts were also detectable in the DLD-1.TA14 control cells, thereby indicating that DLD-1 cells have some endogenous apoL1 expression (Fig. 2A). To confirm the induction of apoL1 expression at the protein level, we conducted immunoblot analysis on induced DLD-1.apoL1 cells using anti-apoL1 antibody. As shown in Fig. 2B, the amount of apoL1 protein was greatly increased (>6-fold) 12 h after the induction. We then investigated whether overexpression of apoL1 could promote cell death. As shown in Fig. 2C, induction of apoL1 in DLD-1.apoL1 cells had a negative effect on cell proliferation significantly reducing the growth rate at 48 h when grown in the absence of Dox (D.0; Fig. 2, C, 4th column, and D). Dying/dead cells showed a change in cell morphology, increasing intracellular vacuoles, and detachment from culture plates. In contrast, DLD-1.apoL1 cells grown in D.20 exhibited normal growth (Fig. 2, C, 1st column, and D). Similar results were observed in DLD-1.apoL1.FLAG cells (data not shown). Because apoL1 expression was Tet-Off-regulated by the concentration of Dox in the culture medium, a cell

growth study was conducted at various concentrations of Dox. In the presence of gradually increasing Dox concentrations, such as 1 ng/ml (D.1) and 5 ng/ml (D.5), cell death was decreased in DLD-1.apoL1 cells, implying that the cell death rate was related to the level of apoL1 expression. Furthermore, to investigate the importance of the BH3 domain of apoL1 in the induction of cell death, we constructed adenovirus harboring WT apoL1 (AD-apoL1) or a BH3 domain deletion mutant of apoL1 (AD-apoL1.dBH3) and used those to infect a variety of cell types, including HEK293 cells. As shown in Fig. 3A, cells overexpressing green fluorescence protein also overexpressed apoL1 protein. It is evident that greater than 95% of cells infected with AD-apoL1 were dead, same as those inducing DLD-1.apoL1 cells, 72 h after infection (Fig. 3A, panels b and e). In contrast, AD only or AD-apoL1.dBH3 failed to induce cell death (Fig. 3A, panels a and d, and c and f, respectively). Immunoblot analysis showed the

protein products of WT apoL1 and apoL1.dBH3 were made in a time-dependent manner and were stable (Fig. 3B, 3rd and 6th lanes for WT apoL1 and 4th and 7th lanes for apoL1.dBH3). In addition, endogenous expression of apoL1 was very low in HEK293 cells with or without AD infection (Fig. 3B, 1st, 2nd, and 5th lanes). Identical results were observed for the same set of experiments in four different cell lines, DLD-1, HepG2 (liver cancer), MCF-7 (breast cancer), and LNCaP, PC3, and DU145 (prostate cancer) (data not shown). Thus, AD-apoL1 is a potent inducer of AuCD in a variety of cells and may be a general autophagy mediator.

ApoL1-induced Cell Death Is Not through Caspase-dependent Apoptosis—Because apoL1 and apoL6 have high sequence and structure similarity and apoL6 induces caspase-dependent apoptosis, we examined whether apoL1-induced cell death was mediated through apoptosis. Fig. 4 showed that caspases 9 and 3 were not activated, and PARP, a well known substrate of caspases, was not cleaved during apoL1-induced cell death in DLD-1.apoL1 cells (Fig. 4A). By contrast, apoptotic DLD-1.apoL6 cells showed activation of caspase 9 8 h after apoL6 induction, which is consistent with previous findings (45).

ApoL1 Induces Activation and Translocation of LC3-II—To investigate whether apoL1-induced cell death acted through autophagy, we analyzed apoL1-induced activation and translocation of LC3-II to AV, a critical step in autophagic pathway. The amount of LC3-II has been shown previously to correlate with the number of AV (13, 14, 51). Immunoblot analysis of LC3 indicated a time-dependent accumulation of LC3-II and increase in the ratios of LC3-II to LC3-I in induced and auto-




FIGURE 3. BH3 domain deletion construct of apoL1 failed to induce cell death in DLD-1 cells. *A*, adenoviruses harboring WT apoL1 (AD-apoL1) and BH3 domain deletion mutant of apoL1 (AD-apoL1.dBH3) were constructed and used to infect DLD-1 cells. Cells overexpressing green fluorescence protein also overexpressed apoL1 protein. AD-apoL1 induced cell death 72 h after infection (*panels b* (bright field) and *e*). In contrast, AD only or AD-apoL1.dBH3 failed to induce cell death (*panels a* (bright field) and *d*, and *c* (bright field) and *f*, respectively). *B*, time-dependent protein production of WT apoL1 and apoL1.dBH3. Hours after infection were as indicated. Note that endogenous expression of apoL1 was very low, almost undetectable, in DLD-1 cells (1st, 2nd, and 5th lanes). Both proteins were stably produced in time-dependent manner (3rd and 6th and 4th and 7th lanes for WT apoL1 and apoL1.dBH3, respectively). β-Actin was used as a loading control.




FIGURE 4. ApoL1-induced cell death is through autophagy, not by apoptosis. *A*, caspases 9 and 3 were not activated, and PARP was not cleaved during apoL1-induced cell death. By contrast, apoL6 induces cell death through apoptosis by activation of caspases 9 as described previously (45). *B*, apoL1 induced activation and translocation of LC3. Immunoblot analysis of LC3 in autophagic DLD-1.apoL1 cells. Total soluble proteins were isolated at indicated time points from DLD-1.apoL1 cells cultured in induction medium. Times after induction of apoL1 are as indicated. Accumulation of LC3-II in induced DLD-1.apoL1 cells can be seen 12 h after induction. The ratios between LC3-II and LC3-I were 0.1, 2, and 20, 0, 12, and 24 h after induction, respectively. *C*, immunofluorescence staining of LC3 (red) in DLD-1.apoL1 cells. *Panel a*, DLD-1.apoL1 cells cultured in normal medium, and *panel b*, DLD-1.apoL1 cells cultured in induction medium for 24 h. At least 300 cells were analyzed for each experiment.




FIGURE 5. ApoL1 induces accumulation of AV and autophagic cell death, which can be inhibited by 3-MA and wortmannin. *A*, effect of 3-MA (5 mM) and wortmannin (1 μg/ml) on apoL1-induced cell death was observed by light microscopy analysis. 3-MA and wortmannin were added to noninduction medium 8 h prior to the induction of apoL1. *Panel a*, DLD-1.apoL1 cells in noninduction (regular) medium; *panel b*, in induction medium; *panel c*, in induction medium + 3-MA; and *panel d*, in induction medium + wortmannin. Obviously, 3-MA and wortmannin partially blunt apoL1-induced cell death in DLD-1.apoL1 cells by 55 and 40%, respectively. All the images were taken by the same inverted microscope (Olympus, CK40) with a MacroFire digital camera (OPTRONIC, model S99831). *B*, electron microscopy analysis of autophagic DLD-1.apoL1 cells. *Panel a*, control DLD-1.apoL1 cells; *panels b* and *c*, autophagic DLD-1.apoL1 cells under two different magnifications; *panels d–f*, magnified views of vacuoles in the cell shown in *panel c*. *Panel d*, an enlarged empty vacuole; *panel e*, a double-membraned structure presumably an autophagosome; *panel f*, an AV, presumably an autolysosome, engulfing an electron-dense body. Scale bars are as indicated. Data are representative of four experiments. Each experiment was repeated at least three times.

phagic DLD-1.apoL1 cells (Fig. 4*B*). After induction of apoL1, the ratios of LC3-II and LC3-I were 1:10, 2:1, and 20:1 0, 12, and 24 h, respectively. In addition, immunofluorescence microscopy analysis showed a pattern of punctate staining of LC3-II in induced DLD-1.apoL1 cells (Fig. 4*C*, *panel b*), indicating the translocation of LC3-II from cytosol to AV. In contrast, control DLD-1.apoL1 cells showed a cytosolic staining pattern of LC3 (Fig. 4*C*, *panel a*), which indicates physiological localization of LC3-I in normal cells.

ApoL1 Induces Increased Formation of AV and Autophagy Which Can Be Inhibited by 3-MA and Wortmannin—Transmission electron microscopy (TEM) is one of the most sensitive and definitive methods to detect autophagic compartments in mammalian cells (52, 53). To further confirm that apoL1-induced cell death was indeed through autophagy, we conducted both light microscopy and TEM analyses. Normal DLD-1.apoL1 cells under light microscopy and TEM were displayed in Fig. 5, *A*, *panel a*, and *B*, *panel a*, respectively. Induced DLD-1.apoL1 cells with increased expression of apoL1 showed significant formation of AV under the TEM (Fig. 5*B*, *panels b* and *c*). The magnified images showed an enlarged empty vacuole (Fig. 5*B*, *panel d*), a double-membraned AV (Fig. 5*B*, *panel e*), and an autophagosome engulfing an electron-dense body (Fig. 5*B*, *panel f*) in an induced DLD-1.apoL1 cell (Fig. 5*B*, *panel c*). Induced DLD-1.apoL1 cells were deformed and slightly




FIGURE 6. ApoL1 fails to induce cell death in autophagy-deficient ATG5^{-/-} and ATG7^{-/-} MEFs. Wild type (WT), ATG5^{-/-}, and ATG7^{-/-} MEF cells were grown in Dulbecco's modified Eagle's medium to 30% confluence, infected with control AD or AD-apoL1 viruses for 36 h, and followed by light microscopy analysis (A). Greater than 90% of WT MEF cells infected with AD-apoL1 had died, whereas less than 20% of the ATG5^{-/-} or ATG7^{-/-} (not shown) cells were dead. B, immunoblot analysis showed overexpression of apoL1 protein was achieved at 36 h after infection of AD-apoL1 in ATG7^{-/-}, WT, and ATG5^{-/-} MEFs. Importantly, apoL1 again induced activation of LC3 II and increased the ratio of LC3-II to LC3-I (6th lane). By contrast, apoL1 failed to induce activation of LC3 in the ATG5^{-/-} and ATG7^{-/-} cells. Of note, it has been reported that MEFs have high endogenous LC3-II (15, 16).

enlarged under the light microscopy (Fig. 5A, panel b). In addition, we examined the effect of 3-MA and wortmannin, two inhibitors of PI3Ks and autophagy (13, 14, 54), on apoL1-induced cell death. Fig. 5A, panels c and d, showed that 3-MA and wortmannin partially blunt apoL1-induced cell death in DLD-1.apoL1 cells cultured in induction medium. These data suggest that apoL1-induced cell death can be blocked by inhibitors of autophagy.

ApoL1 Fails to Induce Cell Death in Autophagy-deficient MEFs—To further confirm apoL1 induces AuCD, two well studied, autophagy-deficient MEFs, ATG5^{-/-} and ATG7^{-/-}, were used. It has been well documented that ATG5 and ATG7 are essential for the initiation of autophagosome formation. ATG5 is an acceptor molecule for the ubiquitin-like molecule ATG12, and the proper conjugation of ATG5 with ATG12 is required for the elongation of the autophagic membrane (15). ATG7, an E1-like enzyme, together with ATG10, an E2-like enzyme, catalyze the covalently conjugated complex of ATG5-ATG12. In addition, ATG7 is required for the lipidation/activation of LC3-II and subsequently translocation of LC3-II to the




FIGURE 7. Expression of apoL1 is up-regulated by p53 in p53-induced cell death. Immunoblot analysis of time-dependent expression of apoL1 under the influence of p53 was assayed. Overexpression of p53 was achieved in DLD-1.p53 cells and in Hec50co cells as described previously (45). Hours after p53 overexpression are as indicated. Induction of apoL1 was detected 8 and 12 h after p53 overexpression in DLD-1.p53 cells and Hec50co cells, respectively. β-Actin was used as loading control.

autophagic membrane (10, 16). Thus, cells lacking either ATG5 or ATG7 are defective in LC3-II activation and autophagosome formation. MEF cells were infected with AD-apoL1 for 36 h at which point induction of apoL1, cell death, and LC3 activation were assayed. Fig. 6A showed that greater than 90% of WT MEF cells infected with AD-apoL1 had died, whereas less than 20% of the ATG5^{-/-} cells were dead. Fig. 6B showed overexpression of apoL1 protein was achieved at 36 h after infection of AD-apoL1 in ATG5^{-/-}, ATG7^{-/-}, and WT MEFs. Importantly, apoL1 again induced activation of LC3 II and increased the ratio of LC3-II to LC3-I in WT MEF cells (Fig. 6B, 6th lane). By contrast, apoL1 failed to induce activation of LC3 and autophagy, as expected, in both the ATG5^{-/-} and ATG7^{-/-} cells. These results further indicate that apoL1-induced cell death is autophagy-dependent.

Expression of ApoL1 Is Up-regulated by P53 in P53-induced Cell Death—Previous studies showed that p53, one of the master regulators in PCD, induces both apoptosis and autophagy (39, 40). To investigate whether the expression of apoL1 was regulated by p53, we took advantage of two of our previously used cancer cell models, DLD-1.p53 and Hec50co, in p53-induced apoptosis. Overexpression of p53 was achieved in DLD-1.p53 cells by Tet-Off induction and in Hec50co cells by AD-p53 infection as described previously (44). Immunoblot analysis showed time-dependent expression of apoL1 under the influence of p53 in both cell lines. As shown in Fig. 7, induction of apoL1 was detected 8 and 12 h after p53 overexpression in DLD-1.p53 cells and Hec50co cells, respectively, and 16 and 12 h prior to p53-induced cell death in DLD-1.p53 cells and Hec50co cells, respectively. This indicates that apoL1 is inducible by p53 during p53-induced cell death.

ApoL1 Binds Strongly with PA and CL and Less with Some Phosphoinositides—To explore the binding of apoL1 to lipids, apoL1.FLAG fusion protein was first immunoprecipitated by anti-FLAG antibody and subsequently eluted by 3× FLAG peptide. The purified apoL1.FLAG protein was confirmed by immunoblot analysis using anti-FLAG or anti-apoL1 antibodies (Fig. 8A) and was subsequently used for protein lipid overlay assay. Two membranes pre-spotted with a variety of lipid species were probed with the apoL1.FLAG fusion protein. As expected, Fig. 8B showed that the apoL1.FLAG, but not 3× FLAG itself (negative control), bound to a variety of lipid species immobilized on the nitrocellulose membranes *in vitro*. The apoL1.FLAG showed strong binding affinity for PA and CL but




FIGURE 8. Interacting lipid species of apoL1.FLAG protein. Affinity-purified apoL1.FLAG fusion protein was used to conduct lipid overlay assay (see "Experimental Procedures" for details). $3 \times$ FLAG peptide solution was used as a negative control. **A**, purified apoL1.FLAG was confirmed by immunoblot analysis using both anti-apoL1 and anti-FLAG antibodies. **B**, apoL1.FLAG bound strongly with CL and PA, followed by PI-3,5- P_2 , PI4P, PI5P, PI3P, PI-4,5- P_2 , PI-3,4,5- P_3 , PI-3,4- P_2 , 3-sulfogalactosylceramide (3-SG Cer), phosphoserine, PG, and PI (very weak). ApoL1.FLAG did not bind cholesterol (CHO), TG, PE, PC, SM, diacylglycerol (DAG), sphingosine 1-phosphate, lysophosphatidic acid (LPA), and lysophosphocholine (LPC). Lipid abbreviations are as follows: TG (triglyceride), PI (phosphatidylinositol), DAG (diacylglycerol), PI4P (PtdIns(4)P), PA (phosphatidic acid), PI4,5P2 (PtdIns(4,5)P₂), PS (phosphatidylserine), PI3,4,5P3 (PtdIns(3,4,5)P₃), PE (phosphatidylethanolamine), CHO (cholesterol), PC (phosphatidylcholine), SM (sphingomyelin), PG (phosphatidylglycerol), 3-SG Cer (3-sulfogalactosylceramide (Sulfatide)), CL (cardiolipin), S1P (sphingosine 1-phosphate), LPA (lysophosphatidic acid), LPC (lysophosphocholine), PI3,4P3 (PtdIns(3,4)P₂), PI3,5P2 (PtdIns(3,5)P₂), PI3P (PtdIns(3)P), PI4P (PtdIns(4)P), PI5P (PtdIns(5)P), and Solvent blank (Blank).

less affinity with different species of PIPs and other phospholipids in the following order: phosphatidylinositol 3,5-bisphosphate (PI-3,5- P_2) > PI4P > PI5P > PI3P > PI-4,5- P_2 > PI-3,4,5- P_3 > PI-3,4- P_2 > 3-sulfogalactosylceramide > phosphoserine > phosphoglycerol (PG) > phosphoinositol (PI) (Fig. 8B). Interestingly, apoL1 did not bind cholesterol, phosphoethanolamine (PE), phosphocholine (PC), sphingomyelin (SM), triglyceride (TG), diacylglycerol, sphingosine 1-phosphate, lysophosphatidic acid, and lysophosphocholine.

DISCUSSION

The role of the Bcl-2 family in regulating apoptosis is well studied; however, its role in mediating AuCD is still elusive. In an effort to identify and characterize novel BH3-only proteins in AuCD, we identified a novel BH3-only pro-death protein apolipoprotein L1 (apoL1) *in silico*. Subsequently we showed that WT apoL1 induces AuCD in a variety of cells, whereas the BH3 deletion construct of apoL1 failed to induce cell death.

Interestingly, apoL1 protein has been found both inside the cells and circulating in the blood. When it is in the serum, apoL1 binds apolipoprotein A-I and is one of the components of high density lipoprotein (HDL) particles, suggesting apoL1 has a role in lipid metabolism (48, 49). In addition, protein secondary structure analysis identified four lipid-

binding amphipathic α -helices in apoL1, which may function as a catalyst for intra- and extracellular lipid transfer (48–50). Importantly, we previously reported that apoL6, a closely related protein of apoL1 and a BH3-only pro-death protein, induces mitochondria- and caspase-mediated apoptosis (45). By contrast we showed apoL4, another member of the apoL family not possessing BH3 domain, failed to induce cell death. Sequence analysis showed that six of the nine residues of the BH3 domain are identical between apoL1 and apoL6 (Fig. 1A). In addition, the BH3 domain of apoL1 showed an amphipathic α -helical structure similar to other known BH3 domains, including that of apoL6. Taken together, our results indicated that both apoL1 and apoL6 are *bona fide* BH3-only pro-death proteins. ApoL1 and apoL6 possess conserved primary sequence and tertiary structure; nevertheless, they function differently and nonredundantly in the induction of PCD. ApoL6 induces apoptosis (type I), whereas apoL1 induces autophagy (type II). It is not unreasonable to postulate that their interacting partners, protein and/or lipid species, play important role in

mediating different death-signaling pathways. As a matter of fact, we showed that apoL1 has very strong affinity for PA and CL. CL is a dimer of PG and PA and includes four acyl chains, two phosphate groups, and three glycerols. As apoL1 binds strongly with PA, it is logical to speculate that apoL1 binds CL through its PA moiety. Interestingly, Fang *et al.* (55) previously showed that PA is a critical component of mammalian target of rapamycin (mTOR) signaling. They showed mitogenic stimulation of mammalian cells led to a phospholipase D-dependent accumulation of cellular PA, which was required for activation of mTOR downstream effectors. PA directly interacted with the domain in mTOR that is targeted by rapamycin, and this interaction was positively correlated with the ability of mTOR to activate downstream effectors. It has also been shown that mTOR is a negative regulator of autophagy (40, 56). Thus, binding of PA by apoL1 might inhibit mTOR activation and subsequently induce autophagy. In addition, accumulating evidence suggests that CL has active roles in mitochondria-mediated apoptosis (57). Binding of CL with apoL1 may prevent apoptosis in favor of induction of AuCD.

PIPs play critical roles in regulating cellular signaling pathways. The homeostatic equilibrium of PIPs determines cellular proliferation, differentiation, trafficking, and PCD (58, 59). It has been shown that PI4P is the most abundant member of

PIPs. Furthermore, PI-3,4,5-P₃ and PI-3,4-P₂ can induce cell growth through the Akt pathway, but PI3P has been shown to induce autophagy and endosomal trafficking. Our results showed that binding of apoL1 to various species of PIPs may alter the homeostasis of PIPs leading to the AuCD. Interestingly, we found that apoL1 did not bind cholesterol, TG, PC, PE, or SM, the major lipid components in HDL (Fig. 8B). It has been shown that apoL1, a minor protein component, can directly interact with apoAI, the major protein component in HDL (48). It is logical to postulate that apoL1, which does not interact with HDL lipid species, binds and modulates the activities of apoAI. To our best knowledge, apoL1 is the first BH3-only, lipid-binding apolipoprotein that induces AuCD.

Interestingly, the genes encoding apoLs are localized to chromosome 22q12.3-13.1, a high susceptibility locus for schizophrenia. Importantly, expression of apoL1 has been shown to be significantly up-regulated (>1.41-fold) in the brains of schizophrenics (60). It will be interesting to see whether overexpression of apoL1 induces AuCD in central nervous system cells, and if so what role of apoL1 plays in the etiology of schizophrenia.

ApoL1 was recently found to be the trypanosome lytic factor in human serum. The parasite *Trypanosoma brucei rhodesiense* causes human sleeping sickness in Africa. The molecular basis of this disease is the product of resistance-associated protein, an inhibitory protein that binds specifically to apoL1 to prevent cell lysis. Unsequestered apoL1 promotes forming anion channels on lysosomal membranes of trypanosome and subsequently kills the parasite (61, 62). Thus, in addition to the aforementioned functions, apoL1 can also play an important role in innate immunity.

It is well documented that LC3 is required for complete autophagosome formation during autophagic pathway in mammalian cells. The combination of alteration of subcellular localization of LC3-II with increased ratio of LC3-II to LC3-I is one of the hallmarks of autophagy (13, 14). This study demonstrates that apoL1 is a potent and specific inducer of AuCD that stimulates time-dependent accumulation and translocation of LC3-II, formation of the AV (confirmed by TEM analysis), and subsequently cell death in apoL1-overexpressing cells. Importantly, no apoptotic hallmarks, such as release of apoptogenic factors from mitochondria or activation of caspases, were detected in apoL1-induced cell death. We also showed that expression of apoL1 is inducible by p53, a well known tumor suppressor and transactivating factor frequently mutated in cancers, which regulates both types of PCD (38–41). Regarding the role of p53 in autophagy, it has been shown that direct activation of p53 by nutrient starvation and serum deprivation induces autophagy in cancer cells (40). In addition, damage-regulated autophagy modulator, a p53 target gene encoding a lysosomal protein, has been shown to be involved in the induction of autophagy (63). Furthermore, Bad and Bid, two BH3-only proteins and direct downstream effectors of p53, not only play important roles in apoptosis but also in autophagy (34, 36, 37). Our results suggest that apoL1 is a novel BH3 only protein and is a p53 downstream effector functioning as a molecular determinant that dictates autophagy for death (Fig. 9).




FIGURE 9. **Hypothetical model of apoL1-induced autophagic death in cancer cells.** Expression of apoL1 is inducible by p53, a tumor suppressor gene. Intracellular accumulation of apoL1 alters lipid homeostasis and signaling, induces activation and translocation of LC3, and generation of autophagic vacuoles leading to cell death. Inhibitors of autophagy, such as 3-MA or wortmannin, blunt apoL1-induced autophagic cell death.

Regarding other BH3-only proteins in PCD, Beclin1 interacts with anti-apoptotic Bcl-2 by virtue of its BH3 domain, an amphipathic α -helix, that binds to the hydrophobic cleft of Bcl-2. Interestingly, the association of Beclin1 with Bcl-2 is of low affinity (1–2 μ M) as compared with other BH3-only proteins that bind to Bcl-2 (in low nanomolar range) (32–34). In fact, it has been shown that Bad, as well as BH3-mimetic compounds such as ABT737, competitively disrupt the inhibitory interaction between Beclin1 and Bcl-2 (34). Thus, it is logical to speculate that when the other BH3-only proteins, such as apoL1 and apoL6, are induced by various stimuli/stresses, they can displace Beclin1, rendering the cell susceptible to autophagy as well as apoptosis, respectively. It will be of interest to investigate whether apoL1 and apoL6 interact with anti-death Bcl-2 family members and the functional consequences of the interactions in PCD. Finally, apoL1 provides an excellent model to further study the molecular basis of gene-induced AuCD.

Acknowledgments—We thank Dr. Steven Jett and Tamara Howard for their excellent EM service at the EM Core Facility, University of New Mexico School of Medicine.

REFERENCES

1. Tsujimoto, Y. (2003) *J. Cell. Physiol.* **195**, 158–167
2. Adams, J. M., and Cory, S. (2007) *Curr. Opin. Immunol.* **19**, 488–496
3. Scorrano, L., and Korsmeyer, S. J. (2003) *Biochem. Biophys. Res. Commun.* **304**, 437–444
4. Huang, D. C., and Strasser, A. (2000) *Cell* **103**, 839–842
5. Chipuk, J. E., Bouchier-Hayes, L., and Green, D. R. (2006) *Cell Death Differ.* **13**, 1396–1402
6. Danial, N. N., and Korsmeyer, S. J. (2004) *Cell* **116**, 205–219
7. Maiuri, M. C., Zalckvar, E., Kimchi, A., and Kroemer, G. (2007) *Nat. Rev.*

- Mol. Cell Biol.* **8**, 741–752
8. Tsujimoto, Y., and Shimizu, S. (1995) *Cell Death Differ.* **12**, 1528–1534
 9. Shintani, T., and Klionsky, D. J. (2004) *Science* **306**, 990–995
 10. Mizushima, N. (2007) *Genes Dev.* **21**, 2861–2873
 11. Cuervo, A. M. (2004) *Trends Cell Biol.* **14**, 70–77
 12. Levine, B., and Klionsky, D. J. (2004) *Dev. Cell* **6**, 463–477
 13. Mizushima, N., Ohsumi, Y., and Yoshimori, T. (2002) *Cell Struct. Funct.* **27**, 421–429
 14. Xie, Z., and Klionsky, D. J. (2007) *Nat. Cell Biol.* **9**, 1102–1109
 15. Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., Ohsumi, Y., Tokuhisa, T., and Mizushima, N. (2004) *Nature* **432**, 1032–1036
 16. Komatsu, M., Waguri, S., Ueno, T., Iwata, J., Murata, S., Tanida, I., Ezaki, J., Mizushima, N., Ohsumi, Y., Uchiyama, Y., Kominami, E., Tanaka, K., and Chiba, T. (2005) *J. Cell Biol.* **169**, 425–434
 17. Gozuacik, D., and Kimchi, A. (2004) *Oncogene* **23**, 2891–2906
 18. Kondo, Y., Kanzawa, T., Sawaya, R., and Kondo, S. (2005) *Nat. Rev. Cancer* **5**, 726–734
 19. Levine, B., and Deretic, V. (2007) *Nat. Rev. Immunol.* **7**, 767–777
 20. Paludan, C., Schmid, D., Landthaler, M., Vockerodt, M., Kube, D., Tuschl, T., and Munz, C. (2005) *Science* **307**, 593–596
 21. Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M. T., Michel, P. P., Marquez, J., Mouatt-Prigent, A., Ruberg, M., Hirsch, E. C., and Agid, Y. (1997) *Histol. Histopathol.* **12**, 25–31
 22. Kaneda, D., Sugie, K., Yamamoto, A., Matsumoto, H., Kato, T., Nonaka, I., and Nishino, I. (2003) *Neurology* **61**, 128–131
 23. Berry, D. L., and Baehrecke, E. H. (2007) *Cell* **131**, 1137–1148
 24. Shimizu, S., Kanaseki, T., Mizushima, N., Mizuta, K., Arakawa-Kobayashi, S., Thompson, C. B., and Tsujimoto, Y. (2004) *Nat. Cell Biol.* **6**, 1221–1228
 25. Pattingre, S., Tassa, A., Qu, X., Garuti, R., Liang, X. H., Mizushima, N., Packer, M., Schneider, M. D., and Levine, B. (2005) *Cell* **122**, 927–939
 26. Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. (2001) *Science* **292**, 727–730
 27. Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., Strasser, A., Kluck, R. M., Adams, J. M., and Huang, D. C. (2007) *Science* **315**, 856–859
 28. Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., and Levine, B. (1999) *Nature* **402**, 672–676
 29. Pattingre, S., and Levine, B. (2006) *Cancer Res.* **66**, 2885–2888
 30. Yue, Z., Jin, S., Yang, C., Levine, A. J., and Heintz, N. (2003) *Proc. Natl. Acad. Sci. U. S. A.* **100**, 15077–15082
 31. Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E. L., Mizushima, N., Ohsumi, Y., Cattoretti, G., and Levine, B. (2003) *J. Clin. Invest.* **112**, 1809–18020
 32. Oberstein, A., Jeffrey, P. D., and Shi, Y. (2007) *J. Biol. Chem.* **282**, 13123–13132
 33. Maiuri, M. C., Le Toumelin, G., Criollo, A., Rain, J. C., Gautier, F., Juin, P., Tasdemir, E., Pierron, G., Troulinaki, K., Tavernarakis, N., Hickman, J. A., Geneste, O., and Kroemer, G. (2007) *EMBO J.* **26**, 2527–2539
 34. Maiuri, M. C., Criollo, A., Tasdemir, E., Vicencio, J. M., Tajeddine, N., Hickman, J. A., Geneste, O., and Kroemer, G. (2007) *Autophagy* **3**, 374–376
 35. Lamparska-Przybylska, M., Gajkowska, B., and Motyl, T. (2005) *J. Physiol. Pharmacol.* **56**, Suppl. 3, 159–179
 36. Fei, P., Wang, W., Kim, S. H., Wang, S., Burns, T. F., Sax, J. K., Buzzai, M., Dicker, D. T., McKenna, W. G., Bernhard, E. J., and El-Deiry, W. S. (2004) *Cancer Cell* **6**, 597–609
 37. Hamacher-Brady, A., Brady, N. R., Logue, S. E., Sayen, M. R., Jinno, M., Kirshenbaum, L. A., Gottlieb, R. A., and Gustafsson, A. B. (2007) *Cell Death Differ.* **14**, 146–157
 38. Chipuk, J. E., and Green, D. R. (2006) *Cell Death Differ.* **13**, 994–1002
 39. Lum, J. J., Bauer, D. E., Kong, M., Harris, M. H., Li, C., Lindsten, T., and Thompson, C. B. (2005) *Cell* **120**, 237–248
 40. Levine, A. J., Feng, Z., Mak, T. W., You, H., and Jin, S. (2006) *Genes Dev.* **20**, 267–275
 41. Gu, S., Liu, Z., Pan, S., Jiang, Z., Lu, H., Amit, O., Bradbury, E. M., Hu, C. A., and Chen, X. (2004) *Mol. Cell. Proteomics* **3**, 998–1008
 42. Liu, Z., Lu, H., Shi, H., Du, Y., Yu, J., Gu, S., Chen, X., Liu, K. J., and Hu, C. A. (2005) *Cancer Res.* **65**, 1647–1654
 43. Hu, C. A., Donald, S. P., Yu, J., Lin, W. W., Liu, Z., Steel, G., Obie, C., Valle, D., and Phang, J. M. (2007) *Mol. Cell. Biochem.* **295**, 85–92
 44. Liu, Z., Wan, G., Heaphy, C., Bisoffi, M., Griffith, J. K., and Hu, C. A. (2007) *Mol. Cell. Biochem.* **297**, 179–187
 45. Liu, Z., Lu, H., Jiang, Z., Pastuszyn, A., and Hu, C. A. (2005) *Mol. Cancer Res.* **3**, 21–31
 46. Bystroff, C., and Shao, Y. (2002) *Bioinformatics (Oxf.)* **18**, S54–S61
 47. Bystroff, C., Thorsson, V., and Baker, D. (2000) *J. Mol. Biol.* **301**, 173–190
 48. Duchateau, P. N., Pullinger, C. R., Orellana, R. E., Kunitake, S. T., Naya-Vigne, J., O'Connor, P. M., Malloy, M. J., and Kane, J. P. (1997) *J. Biol. Chem.* **272**, 25576–25582
 49. Duchateau, P. N., Pullinger, C. R., Cho, M. H., Eng, C., and Kane, J. P. (2001) *J. Lipid Res.* **42**, 620–630
 50. Page, N. M., Butlin, D. J., Lomthaisong, K., and Lowry, P. J. (2001) *Genomics* **74**, 71–78
 51. Kabeya, Y. (2000) *EMBO J.* **19**, 5720–5728
 52. Klionsky, D. J., Cuervo, A. M., and Seglen, P. O. (2007) *Autophagy* **3**, 181–206
 53. Eskelinen, E.-L. (2005) *Autophagy* **1**, 1–10
 54. Seglen, P. O., and Gordon, P. B. (1982) *Proc. Natl. Acad. Sci. U. S. A.* **79**, 1889–1892
 55. Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., and Chen, J. (2001) *Science* **294**, 1942–1945
 56. Backer, J. M. (2008) *Biochem. J.* **410**, 1–17
 57. Gonsalvez, F., and Gottlieb, E. (2007) *Apoptosis* **12**, 877–885
 58. Sasaki, T., Sasaki, J., Sakai, T., Takasuga, S., and Suzuki, A. (2007) *Biol. Pharm. Bull.* **30**, 1599–1604
 59. Wymann, M. P., and Schneider, R. (2008) *Nat. Rev. Mol. Cell Biol.* **9**, 162–176
 60. Mimmack, M. L., Ryan, M., Baba, H., Navarro-Ruiz, J., Iritani, S., Faull, R. L., McKenna, P. J., Jones, P. B., Arai, H., Starkey, M., Emson, P. C., and Bahn, S. (2002) *Proc. Natl. Acad. Sci. U. S. A.* **99**, 4680–4685
 61. Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D. P., Lins, L., Van Den Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., Moguilevsky, N., Dieu, M., Kane, J. P., De Baetselier, P., Brasseur, R., and Pays, E. (2003) *Nature* **422**, 83–87
 62. Perez-Morga, D., Vanhollebeke, B., Paturiaux-Hanocq, F., Nolan, D. P., Lins, L., Homble, F., Vanhamme, L., Tebabi, P., Pays, A., Poelvoorde, P., Jacquet, A., Brasseur, R., and Pays, E. (2005) *Science* **309**, 469–472
 63. Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., and Ryan, K. M. (2006) *Cell* **126**, 121–134

Published in final edited form as:

Autophagy. 2008 November 16; 4(8): 1079–1082.

ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death

Siqin Zhaorigetu[#], Guanghua Wan[#], Ramesh Kaini, Zeyu Jiang, and Chien-an A. Hu^{*}

Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, School of Medicine, Albuquerque, NM 87131, USA

Abstract

We recently reported the identification and characterization of a novel BH3-only pro-death protein, apolipoprotein L1 (ApoL1), that, when overexpressed, induces autophagic cell death (ACD) in a variety of cells, including those originated from normal and cancerous tissues. ApoL1 failed to induce ACD in autophagy-deficient Atg5^{-/-} and Atg7^{-/-} MEF cells, suggesting that ApoL1-induced cell death is indeed autophagy-dependent. In addition, a BH3 domain deletion allele of ApoL1 was unable to induce ACD, demonstrating that ApoL1 is a *bona fide* BH3-only pro-death protein. To further investigate regulation of ApoL1 expression, we showed that ApoL1 is inducible by interferon- γ and tumor necrosis factor- α in human umbilical vein endothelial cells, suggesting that ApoL1 may play a role in cytokine-induced inflammatory response. Moreover, we observed that ApoL1 is a lipid-binding protein with high affinity for phosphatidic acid and cardiolipin and less affinity for various phosphoinositides. Functional genomics analysis identified 5 nonsynonymous single nucleotide polymorphisms (NSNPs) in the coding exons of the human ApoL1 structural gene— all the 5 NSNPs may cause deleterious alteration of ApoL1 activity. Finally, we discuss the link between ApoL1 and various human diseases.

Keywords

trypanosomal lytic factor; apolipoprotein L1 (ApoL1); autophagy; autophagic cell death; BH3-only protein; cardiolipin; lipid binding; PIPs; phosphatidic acid; schizophrenia; SNPs

Macroautophagy (hereafter referred to as autophagy) is a lysosome-dependent mechanism of intracellular degradation that is used for the turnover and recycling of cytoplasmic constituents. It involves the sequestration of a fraction of cytosol and organelles within a *de novo* synthesized, double-membraned organelle called the autophagosome, which then fuses with the endosome and/or lysosome to create the amphisome and autolysosome, respectively. Eventually, the inner membrane of the autophagosome, together with the enclosed cargo, is degraded by the lysosomal hydrolases.¹ Autophagy in mammals serves multiple purposes: it functions as a survival mechanism during periods of starvation and stress, it is directly involved in eliminating aberrant protein aggregates, removing damaged/aged organelles, and defending against pathogens, and it serves an essential role in early neonatal development.² Evidently, autophagy also functions as type II programmed cell death (PCD), or autophagic cell death (ACD), in multi-cellular organisms.^{3,4} It has been reported that autophagy is involved in

*Correspondence to: Chien-an A. Hu, Department of Biochemistry and Molecular Biology, MSC08 4670, 1 University of New Mexico, Albuquerque, NM 87131-0001, Tel: (505) 272-8816, Fax: (505) 272-6587; E-mail: AHu@salud.unm.edu.

[#]These authors contributed equally to the work.

Addendum to: Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem. 2008; 283:21540–49.

physiological cell death during development of *Drosophila* and *Dictyostelium discoideum*, however, ACD has not yet been observed/demonstrated in mammals *in vivo*.^{5,6}

In the past two decades, yeast has been used as an experimental model in dissecting the molecular bases of autophagy. Currently 31 ATG (autophagy-related) genes have been identified in yeast.^{3,6} Recent identification and characterization of human orthologs/homologs of yeast ATG genes and the link between autophagy and human diseases further emphasize the importance of autophagy in health and disease. Deficiency of autophagy correlates with diseases such as cancer, cardiomyopathies, inflammatory bowel diseases and neurodegenerative diseases.^{5,7} In addition, autophagy involves unique membrane dynamics and biosynthesis, requiring *de novo* synthesis of double-membrane autophagosomes, in which both protein and lipid components are required. Regarding protein components, aside from Atg proteins, Vps34, a class III phosphatidylinositol-3-phosphate kinase (PI3K), the proteins that are part of its complex, and the Bcl-2 family members play critical roles in regulating autophagosome formation. Interestingly, Beclin 1, the mammalian ortholog of yeast Atg6 that is required for autophagy, is a BH3-only protein. In addition, other Bcl-2 family members, such as Bcl-2, Bax, Bid and BNIP3, regulate autophagy.^{6,8} By contrast, the lipid composition of autophagosomal membranes remains unknown because it is technically difficult to isolate pure autophagosomes. It is evident however that some lipid species, for example, phosphatidylinositol-3-phosphate or PI3P, are required for autophagosomal membranes.^{1,9}

In an effort to identify and characterize novel BH3-only proteins in ACD, and discover molecular regulators that dictate autophagy for death or survival, we examined a novel BH3-only protein, apolipoprotein L1 (ApoL1). We show that wild-type ApoL1 induces ACD in a variety of cells, whereas a BH3 deletion allele of ApoL1 fails to induce cell death, indicating that ApoL1 is a *bona fide* BH3-only pro-death protein. We further demonstrate that ApoL1 is a potent and specific inducer of ACD that stimulates time-dependent accumulation and translocation of lipidated LC3-II, formation of autophagosomes and subsequently cell death. We also show that ApoL1 is inducible by p53 during p53-induced cell death. p53, a well-known tumor suppressor, regulates both apoptosis and ACD.⁴ Interestingly, a recent study shows that p53 plays a dual role in the control of autophagy: on the one hand, nuclear p53 can induce autophagy through transcriptional effects, whereas on the other hand, cytoplasmic p53 may act as a master repressor of autophagy.¹⁰ Our results suggest that ApoL1 is a novel BH3-only protein and is a p53 downstream effector functioning as a molecular determinant that determines whether autophagy plays a role in cell death.⁴ Importantly, ApoL1 has been found only in humans and African green monkeys (NCBI Entrez Gene, ApoL1), suggesting that ApoL1-induced ACD is primate-specific.

Employing a protein-lipid overlay assay, we demonstrate that ApoL1 is an intracellular lipid-binding protein that binds strongly with phosphatidic acid (PA) and cardiolipin (CL), and with less affinity with different species of phosphoinositides (PIPs) in the following order PI(3,5)P₂>PI4P>PI5P>PI3P>PI(4,5)P₂>PI(3,4,5)P₃>PI(3,4)P₂.⁴ PIPs are phosphorylated derivatives of the membrane phospholipids phosphatidylinositols and play critical roles in regulating receptor signaling, cytoskeleton function and membrane trafficking. They are highly concentrated and localized in distinct pools in the plasma membrane, endosomes, nucleus and autophagosomal membranes, where they function as ligands, adaptors or docking sites for PIP-binding proteins. In addition, the homeostatic equilibrium of PIPs determines cellular proliferation, differentiation and PCD.^{11,12} Vps34 is required for autophagy, implying an essential role of its product PI3P in this process.¹³ Recently, Obara and colleagues⁹ showed that PI3P is highly enriched and delivered to autophagosomal membranes but not as a cargo enclosed in autophagosomes, implying direct involvement of PI3P in autophagosome formation. They also report a possible enrichment of PI3P on the inner autophagosomal membranes compared to the outer membrane.⁹ Regarding binding with PIPs, we show that

ApoL1 possesses higher affinity for PI(3,5)P₂, PI4P, PI5P, and PI3P, implying that intracellular accumulation of ApoL1 may alter the homeostasis of PIPs leading to ACD. In addition, we conducted a protein domain homology search and found no homology between ApoL1 and any known PIP-binding domains, including FYVE (Fab1, YOTB, Vac1 and EEA1), PX (Phox homology), PH (Pleckstrin homology), ENTH (Epsin N-terminal homology), FERM (Band4.1, Ezrin, Radixin, and Moesin), GRAM (Glucosyltransferase, Rab-like GTPase Activator, and Myotubularins), ANTH (AP180/CALM), and WD-repeats of WIPIs, human orthologs of yeast Atg18 and/or Atg20.^{7,14,15} In fact, no specific binding domain for PI(3,5)P₂ has been identified thus far. Taken together, ApoL1 may represent a novel class of PIP-binding protein. Importantly, in autophagy, at least 2 Atg proteins are involved in PIP synthesis (Atg6 and Atg14) and 5 Atg proteins bind PIP (Atg18, Atg20, Atg21, Atg24 and Atg27).^{1,7} Evidently, yeast mutant strains deficient in PIP binding will be useful for functional complementation and biochemical analysis of human ApoL1.

Interestingly, ApoL1 also binds PA and CL. PA is a mitogenic messenger that serves as a critical component of mTOR signaling. PA directly interacts with the domain in mTOR that is targeted by rapamycin, and this interaction positively correlates with mTOR's ability to activate downstream effectors. mTOR is a negative regulator of autophagy,^{16,17} thus, binding of PA by ApoL1 might inhibit mTOR activation and subsequently induce autophagy. In addition, CL, a negatively charged phospholipid abundant in the mitochondrial inner membrane, is important in maintaining protein (for example cytochrome c) and membrane integrity of mitochondria. During apoptosis, CL functions as the docking site for t-Bid and Bad and induces mitochondrial membrane permeability and cytochrome c release.^{18,19} In addition, CL relocates to the plasma membrane and other subcellular organelles during cell death.²⁰ Sequestering of PA and CL with ApoL1 may alter the homeostasis between survival and death leading to ACD. To our knowledge, this is the first BH3-only protein with lipid binding activity that, when overproduced intracellularly, induces ACD.

Roles of ApoL1 in human diseases

African Sleeping sickness

The parasites *Trypanosoma brucei rhodesiense* and *Trypanosoma brucei gambiense* cause human sleeping sickness in Africa. It has been known for over a century that human serum contains trypanosomal lytic factor (TLF) that can lyse most of the invading trypanosome species. TLF, residing in a minor subclass of human high-density lipoprotein particles, contains apolipoprotein A-I (ApoA-I) and two primate-specific proteins, ApoL1 and hepatoglobin-related protein (Hrp), both of which are toxic to trypanosomes.^{21,22} The molecular basis of this disease is that pathological trypanosomes produce the serum resistance-associated protein (SRA), an inhibitory protein that binds specifically to ApoL1 to prevent trypanosomal lysis. Unsequestered and engulfed ApoL1 promotes the formation of anion (Cl⁻) channels on lysosomal membranes of trypanosomes and induces osmotic swelling of lysosomes due to massive influx of chloride ions from the cytoplasmic compartment, and subsequently kills the parasite.²¹ In addition to ApoL1 and Hrp, Wildener and colleagues²³ recently provided *in vitro* evidence that hemoglobin is a cofactor of human TLF that increases the affinity of TLF for its receptor, and therefore the internalization efficiency of TLF to the parasite. More importantly, ApoL1 alone is sufficient to confer trypanolytic activity in transgenic mice but both ApoL1 and Hrp are required to increase the specific activity of TLF.²⁴ It is worth noting that a recent case report documents that an Indian patient whose serum lacked trypanolytic activity due to the absence of ApoL1 was infected by a serum-sensitive *T. evansi*, a strain that would normally not infect humans. Mutation analysis shows that the patient possesses two frameshift mutations in both ApoL1 alleles, further emphasizing the critical role of ApoL1 in innate immunity against trypanosomal infection.²² Nevertheless, it is evident that ApoL1-

induced cell death in mammalian cells is through autophagy, not through Cl^- influx and osmotic swelling of the lysosome that happens in trypanosomes and in *E. coli*.^{22,25} Our recent result showed that ApoL1 is localized in the cytosol, not in lysosomes, in mammalian cells (Wan et al., unpublished observation). In addition, ApoL1-induced trypanosomal lysis can be delayed by the anion blocker DIDS (4,4-diisothiocyanatostilbene-2,2-disulfonic acid). It is thought that ApoL1-mediated influx of Cl^- from the cytoplasm to the lysosome causes a change in the cytosolic Cl^- concentration that in turn causes a compensatory movement of extracellular Cl^- across the plasma membrane through DIDS-sensitive channels in trypanosomes.²¹ However, our recent observation indicated that DIDS fails to delay or block ApoL1-induced ACD in mammalian cells (Wan, unpublished observation). As indicated earlier, ApoL1 has been found only in humans and African green monkeys, suggesting that ApoL1-induced ACD is primate specific.

Schizophrenia

The human gene encoding ApoL1 is localized to chromosome 22q13.1, a region with loci that might be linked to susceptibility of schizophrenia. Importantly, expression of ApoL1 is significantly upregulated (>1.41 fold) in the brains of schizophrenics.²⁶ Takahashi and colleagues²⁷ recently performed a family-based association study using 377 families with schizophrenia and 130 SNPs (single nucleotide polymorphisms) associated with the ApoL gene family. They show that seven SNPs have p-values <0.05 in the ApoL1, ApoL2 and ApoL4 regions in 226 families (approximately 60%), suggesting ApoL genes should be more extensively studied in schizophrenia. It will be interesting to see whether overexpression of ApoL1 induces ACD in CNS cells, and if so, what role ApoL1 plays in the etiology of schizophrenia.

Inflammation in atherosclerosis

Atherosclerosis is a chronic inflammatory disease of the vasculature with lesions developing in the arterial wall, and it is governed by a complex network of inter- and intra-cellular signaling pathways. The pleiotropic, pro-inflammatory cytokine interferon- γ (INF- γ) and tumor necrosis factor- α (TNF- α) are key mediators that are highly expressed in atherosclerotic lesions.²⁸ The endothelium, the monolayer covering the inner surface of blood vessels, plays a pivotal role in the regulation of vascular tone and structure, as well as vascular inflammation. Dysfunction of endothelial cells is an early sign of atherosclerosis. Interestingly, previous studies show ApoL1 is strongly induced by INF- γ and TNF- α in endothelial cells at the mRNA level.²⁹ Using human umbilical vein endothelial cells (HUVEC), a model for endothelial cell physiology and pathophysiology, we recently showed that expression of ApoL1 at the protein level was significantly increased 6 h and 12 h after INF- γ and TNF- α treatment, respectively (Figure 1), suggesting that ApoL1 plays a role in inflammatory and cell death response in endothelial cells. It would be of interest to investigate whether expression of ApoL1 is upregulated in human atherosclerotic tissues, and if so, how and why.

Regarding other possible roles of ApoL1 in human disease, in a microarray study Kang and colleagues³⁰ show that ApoL1 is one of the senescence-associated genes that are induced greater than 14-fold in normal human oral keratinocytes undergoing senescence. However, the function of ApoL1 in aging/senescence has not been further explored. To explore possible genetic alterations in ApoL1 that may correlate with human disease, we conducted a SNP analysis by searching/mining the NCBI SNP database. We found NSNPs, G96R, E150K, M228I, R255K, and D337N, in the coding sequence of human ApoL1 that alter amino acid sequences (Figure 2). All 5 of these changes are considered to be drastic. It is not unreasonable to postulate that some of these NSNPs may be associated with human disease state. Future investigation of ApoL1 will focus on its disease association and lipid binding. For example,

whether the BH3 domain of ApoL1 is necessary for lipid binding, and whether binding of different lipid species by ApoL1 is essential for the induction of ACD. Finally, ApoL1-induced ACD provides an excellent model to dissect the molecular basis of autophagy and other molecular determinants, both protein and lipid species, that dictate the control of autophagy for cell survival or death.

Acknowledgements

This work was supported in part by NCI RO1 (5RO1CA106644-01A1) and to C.-A. A. Hu, and by DOD PCRP predoctoral fellowship (W81XWH-08-1-0183) to R. Kaini.

Abbreviations

ANTH, AP180/CALM
 ACD, autophagic cell death
 AV, autophagic vacuoles
 BH, Bcl-2 homology domain
 CL, cardiolipin
 ENTH, epsin N-terminal homology
 FERM, band4.1, ezrin, radixin, and moesin
 FYVE, Fab1p, YOTB, Vac1p and EEA1
 GRAM, Glucosyltransferase, Rab-like GTPase activator, and myotubularins
 LC3, microtubule associated proteins light chain 3
 3-MA, 3-methyladenine
 PA, phosphatidic acid
 PH, pleckstrin homology
 PI, phosphatidylinositol
 PI3K, phosphatidylinositol-3-phosphate kinase
 PIPs, phosphoinositides
 PX, Phox homology
 PCD, programmed cell death
 SNP, single nucleotide polymorphism

References

1. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. *Nat Cell Biol* 2007;9:1102–09. [PubMed: 17909521]
2. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. *Dev Cell* 2004;6:463–77. [PubMed: 15068787]
3. Scarlatti F, Granata R, Meijer AJ, Codogno P. Does autophagy have a license to kill mammalian cells? *Cell Death Differ*. 2008in press
4. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. *J Biol Chem* 2008;283:21540–49. [PubMed: 18505729]
5. Huang J, Klionsky DJ. Autophagy and human disease. *Cell Cycle* 2007;6:1837–49. [PubMed: 17671424]
6. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell* 2008;132:27–42. [PubMed: 18191218]
7. Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. *Annu Rev Pathol* 2008;3:427–55. [PubMed: 18039129]
8. Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. *Autophagy* 2008;4:600–6. [PubMed: 18497563]

9. Obara K, Noda T, Niimi K, Ohsumi Y. Transport of phosphatidylinositol 3-phosphate into the vacuole via autophagic membranes in *Saccharomyces cerevisiae*. *Genes Cells* 2008;13:537–47. [PubMed: 18533003]
10. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F, Kroemer G. Regulation of autophagy by cytoplasmic p53. *Nat Cell Biol* 2008;10:676–87. [PubMed: 18454141]
11. Gonsalvez F, Gottlieb E. Cardiolipin: setting the beat of apoptosis. *Apoptosis* 2007;12:877–85. [PubMed: 17294083]
12. Sasaki T, Sasaki J, Sakai T, Takasuga S, Suzuki A. The physiology of phosphoinositides. *Biol Pharm Bull* 2007;30:1599–1604. [PubMed: 17827706]
13. Petiot A, Ogier-Denis E, Blommaert EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. *J Biol Chem* 2000;275:992–98. [PubMed: 10625637]
14. Lemmon MA. Phosphoinositide recognition domains. *Traffic* 2003;4:201–13. [PubMed: 12694559]
15. Proikas-Cezanne T, Waddell S, Gaugel A, Frickey T, Lupas A, Nordheim A. WIPI-1 α (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. *Oncogene* 2004;23:9314–25. [PubMed: 15602573]
16. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. *Science* 2001;294:1942–1945. [PubMed: 11729323]
17. Hornberger TA, Chu WK, Mak YW, Hsiung JW, Huang SA, Chien S. The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. *Proc Natl Acad Sci U S A* 2006;103:4741–46. [PubMed: 16537399]
18. Lutter M, Fang M, Luo X, Nishijima M, Xie X, Wang X. Cardiolipin provides specificity for targeting of tBid to mitochondria. *Nat Cell Biol* 2000;2:754–61. [PubMed: 11025668]
19. Hekman M, Albert S, Galmiche A, Rennefahrt UE, Fueller J, Fischer A, Puehringer D, Wiese S, Rapp UR. Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14–3–3 protein binding. *J Biol Chem* 2006;281:17321–36. [PubMed: 16603546]
20. Sorice M, Circella A, Cristea IM, Garofalo T, Di Renzo L, Alessandri C, Valesini G, Esposti MD. Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosis. *Cell Death Differ* 2004;11:1133–45. [PubMed: 15181455]
21. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homble F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. *Science* 2005;309:469–72. [PubMed: 16020735]
22. Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, Katti R, Jannin JG, Pays E. Human *Trypanosoma evansi* infection linked to a lack of apolipoprotein L-I. *N Engl J Med* 2006;355:2752–6. [PubMed: 17192540]
23. Widener J, Nielsen MJ, Shiflett A, Moestrup SK, Hajduk S. Hemoglobin is a co-factor of human trypanosome lytic factor. *PLoS Pathog* 2007;3:1250–61. [PubMed: 17845074]
24. Molina-Portela MP, Samanovic M, Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. *J Exp Med* 2008;205:1721–28. [PubMed: 18606856]
25. Vanhollebeke B, Pays E. The function of apolipoproteins L. *Cell Mol Life Sci* 2006;63:1937–44. [PubMed: 16847577]
26. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RL, McKenna PJ, Jones PB, Arai H, Starkey M, Emson PC, Bahn S. Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. *Proc Natl Acad Sci U S A* 2002;99:4680–4685. [PubMed: 11930015]
27. Takahashi S, Cui YH, Han YH, Fagerness JA, Galloway B, Shen YC, Kojima T, Uchiyama M, Faraone SV, Tsuang MT. Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia. *Schizophr Res* 2008;104:153–64. [PubMed: 18632255]

28. Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. *Cytokine* 2005;29:256–69. [PubMed: 15749026]
29. Horrevoets AJ, Fontijn RD, van Zonneveld AJ, de Vries CJ, ten Cate JW, Pannekoek H. Vascular endothelial genes that are responsive to tumor necrosis factor-alpha *in vitro* are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. *Blood* 1999;93:3418–31. [PubMed: 10233894]
30. Kang MK, Kameta A, Shin KH, Baluda MA, Kim HR, Park NH. Senescence-associated genes in normal human oral keratinocytes. *Exp Cell Res* 2003;287:272–81. [PubMed: 12837283]




Figure 1.

Expression of ApoL1 is inducible by interferon- γ (INF- γ) and tumor necrosis factor- α (TNF- α) in HUVEC cells. Immunoblot analysis of the time-dependent expression of ApoL1 under the influence of INF- γ and TNF- α was assayed. Hours (hrs) after treatment are as indicated. Induction of ApoL1 was detected 6 hrs and 12 hrs after INF- γ and TNF- α treatment, respectively. β -actin was used as a loading control.

+1

MEGAALLRVSVLCIWMSALFLGVGVRAEEAGARVQQNVPS

GTD TGDPQSKPLGDWAAGTMDPESSIFIEDAIKYFKEKVS

96

TQNLLLLLLTDNEAWN**G**FVAAAELPRNEADELRKALDNLAR**R**

150

QMIMKDKNWHDKGQQYRNWFLKEFPRLK**SELEDNI****RRLRA****K****LADGVQ**KVHKGTTIANVVSGSLSISSGILTLVGMGLAPFT

228

EGGSLVLLEPGMELGITAALTGITSST**MDYGKK**WWTQAQA

255

IHDLVIKSLDKLKEV**REF**LGENISNFLSLAGNTYQLTRGIG**K**KDIRALRRARANLQSVPHASASRPRVTEPI**SAESGEQ**VER

337

VNEPSILEMSRGVKLT**D**VAPVSFFLVLDVVYLVYESKHLH**N**EGAKSETAEEL**LKKVAQELEEKLNI**LNNNYKILQADQEL**Figure 2.**

Human ApoL1 and its nonsynonymous SNPs. The polypeptide sequence of ApoL1 is shown. Five newly identified NSNPs, G96R, E150K, M228I, R255K, and D337N, are indicated. The BH3 (amino acids 158–166) and leucine zipper (amino acids 365–392) domains are in bold and underlined.